HTX-011减少全膝关节置换术后疼痛与阿片类药物使用:随机2b期试验
结果显示两个HTX-011组在48和72小时疼痛强度均显著低于安慰剂(均P<.001)和单用布比卡因组(P<.05),且出院准备更早、阿片消耗更低,安全性类似。
要点
- HTX-011无针应用于手术部位,72小时内控制释放布比卡因和美洛昔康。
- 与安慰剂和布比卡因HCl相比,HTX-011显著降低48和72小时疼痛强度。
- HTX-011组出院准备更早且72小时阿片消耗更低,安全性类似对照。
核心结论
- 无针应用HTX-011 400mg布比卡因/12mg美洛昔康在初次全膝关节置换术后72小时内较安慰剂和单用布比卡因HCl提供更优的疼痛缓解。
主要发现
- 两个HTX-011组在48和72小时疼痛强度曲线下面积均显著低于安慰剂(均P<.001)。
- 两个HTX-011组在48和72小时疼痛强度均低于单用布比卡因HCl组(P<.05)。
- 罗哌卡因在后关节囊注射仅在前12小时增加小幅初始获益。
- HTX-011组出院准备更早且72小时阿片消耗更低。
- HTX-011单用或联合罗哌卡因耐受良好,安全性类似对照。
关键数值与推荐
- HTX-011剂量为400mg布比卡因/12mg美洛昔康,无针应用于手术部位。
- 对照包括布比卡因HCl 125mg注射和生理盐水安慰剂注射。
- 加用罗哌卡因组为同剂量HTX-011加后关节囊50mg罗哌卡因注射。
- 术后疼痛救援仅允许使用阿片类药物。
临床怎么用
- 对于初次全膝关节置换患者,可考虑术中无针应用HTX-011 400mg布比卡因/12mg美洛昔康以延长术后镇痛并减少阿片消耗。
- 后关节囊加用罗哌卡因可能仅在前12小时提供额外获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HTX-011 is an extended-release, dual-acting local anesthetic consisting of bupivacaine and low-dose meloxicam in a novel polymer that is administered by needle-free application during surgery. The active ingredients are released from the polymer by controlled diffusion over 72 hours. METHODS: This phase 2b, double-blind, placebo-controlled and active-controlled trial enrolled patients undergoing primary unilateral total knee arthroplasty under general anesthesia. Two hundred thirty-two patients were randomized into 4 groups: HTX-011 400 mg bupivacaine/12 mg meloxicam, applied without a needle into the surgical site, the same dose of HTX-011 with a separate 50 mg ropivacaine injection into the posterior capsule, bupivacaine hydrochloride (HCl) 125 mg injection, and saline placebo injection. Only opioids were permitted for postoperative pain rescue. Primary and key secondary endpoints were mean area under the curve of pain intensity scores over 48 hours and 72 hours, respectively, for HTX-011 groups vs placebo. RESULTS: Both HTX-011 groups had significantly reduced mean pain intensity vs placebo through 48 and 72 hours (both P < .001). Ropivacaine added a small initial benefit in the first 12 hours. Both HTX-011 groups also had decreased mean pain intensity vs bupivacaine HCl alone through 48 and 72 hours (P < .05). The HTX-011 groups had significantly earlier discharge readiness along with lower opioid consumption through 72 hours. HTX-011 alone or with ropivacaine was well-tolerated with a safety profile similar to controls. CONCLUSION: Needle-free application of HTX-011 400 mg bupivacaine/12 mg meloxicam provided superior pain reduction through 72 hours after total knee arthroplasty compared with placebo and bupivacaine HCl alone.
引用
- Lachiewicz PF, Lee GC, Pollak RA, et al. HTX-011 Reduced Pain and Opioid Use After Primary Total Knee Arthroplasty: Results of a Randomized Phase 2b Trial. J Arthroplasty. 2020. PMID: 32561266. doi:10.1016/j.arth.2020.05.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。